Pharma shares lose nearly Rs 60,000 crore in one week
Nifty Pharma index down 10.6% during current week, set to post its sharpest decline since Oct 2008
 "Pharma shares lose nearly Rs 60,000 crore in one week")
premium
Investors in pharmaceutical companies have seen wealth erosion of nearly Rs 60,000 crore during the week after a sharp decline in market values of these stocks.
The combined market capitalisation (m-cap) of pharmaceutical companies, which featuring in Nifty Pharma and S&P BSE Healthcare index, has declined by Rs 59,411 crore to Rs 725,697 crore today at 02:45 pm. These companies had total m-cap of Rs 785,108 crore on Friday, May 19, 2017.
Nifty Pharma index trading at three-year low is set to report its biggest fall on weekly basis. The index decline 10.6% thus far in current week, its sharpest decline since October 2008.
Sun Pharmaceutical Industries, Lupin, Dr Reddy’s Laboratories, Aurobindo Pharma, Glenmark Pharmaceuticals and Novartis are notable stocks from 12 companies that hit 52-week lows during the week.
Sun Pharma, the largest loser among pharma stocks in term of m-cap erosion, lost Rs 19,722 crore m-cap in single week. The stock hit a 52-week low of Rs 568 on BSE in intra-day trade today. It tanked 13% after Sun Pharma’s US subsidiary Taro Pharma reported 26% dip in March 2017 quarter (Q4FY17) net sales due to the intense pricing pressure in the US market. Sun Pharma is scheduled to announce its March quarter earnings today.
Lupin, the largest loser in percentage terms, lost m-cap of Rs 9,101 crore. The stock dipped 15% from Rs 1,315 to Rs 1,113, its lowest level since August 2004. The company’s quarterly net profit nearly halved to Rs 380 crore in Q4FY17 from Rs 748 crore in a year ago quarter.
Cipla slipped 13%, lost m-cap of Rs 6,014 crore during the week. Cipla’s performance in 4QFY17 was disappointing, with revenues growing 8% YoY to Rs 360 crore, lower EBITDA margin of 14.1% (sequential decline of around 450bps) and net loss of Rs 60 crore.
Cpla’s India business performance was disappointing, declining 4% YoY. This was driven by de-stocking at the channel level. We believe that CIPLA’s low presence in fast-growing therapies like derma, CNS and anti-diabetics and high vulnerability to price cuts will restrict growth, analysts at HDFC Securities said in result review.
The combined market capitalisation (m-cap) of pharmaceutical companies, which featuring in Nifty Pharma and S&P BSE Healthcare index, has declined by Rs 59,411 crore to Rs 725,697 crore today at 02:45 pm. These companies had total m-cap of Rs 785,108 crore on Friday, May 19, 2017.
Nifty Pharma index trading at three-year low is set to report its biggest fall on weekly basis. The index decline 10.6% thus far in current week, its sharpest decline since October 2008.
Sun Pharmaceutical Industries, Lupin, Dr Reddy’s Laboratories, Aurobindo Pharma, Glenmark Pharmaceuticals and Novartis are notable stocks from 12 companies that hit 52-week lows during the week.
Sun Pharma, the largest loser among pharma stocks in term of m-cap erosion, lost Rs 19,722 crore m-cap in single week. The stock hit a 52-week low of Rs 568 on BSE in intra-day trade today. It tanked 13% after Sun Pharma’s US subsidiary Taro Pharma reported 26% dip in March 2017 quarter (Q4FY17) net sales due to the intense pricing pressure in the US market. Sun Pharma is scheduled to announce its March quarter earnings today.
Lupin, the largest loser in percentage terms, lost m-cap of Rs 9,101 crore. The stock dipped 15% from Rs 1,315 to Rs 1,113, its lowest level since August 2004. The company’s quarterly net profit nearly halved to Rs 380 crore in Q4FY17 from Rs 748 crore in a year ago quarter.
Cipla slipped 13%, lost m-cap of Rs 6,014 crore during the week. Cipla’s performance in 4QFY17 was disappointing, with revenues growing 8% YoY to Rs 360 crore, lower EBITDA margin of 14.1% (sequential decline of around 450bps) and net loss of Rs 60 crore.
Cpla’s India business performance was disappointing, declining 4% YoY. This was driven by de-stocking at the channel level. We believe that CIPLA’s low presence in fast-growing therapies like derma, CNS and anti-diabetics and high vulnerability to price cuts will restrict growth, analysts at HDFC Securities said in result review.
| Company | 19/05/2017 | LTP | % chg | M-cap* |
| Sun Pharma | 652.45 | 570.25 | -12.6 | -19722 |
| Lupin | 1314.90 | 1113.40 | -15.3 | -9101 |
| Cipla | 563.45 | 488.70 | -13.3 | -6014 |
| Aurobindo Pharma | 596.40 | 533.05 | -10.6 | -3712 |
| Dr Reddy's Labs | 2656.05 | 2422.05 | -8.8 | -3878 |
| Cadila Health. | 459.30 | 440.65 | -4.1 | -1909 |
| Piramal Enterp. | 2835.15 | 2718.00 | -4.1 | -2021 |
| Divi's Lab. | 611.35 | 548.10 | -10.3 | -1679 |
| Glenmark Pharma. | 659.85 | 620.50 | -6.0 | -1111 |
| Torrent Pharma. | 1287.05 | 1225.00 | -4.8 | -1050 |
| LTP: Last traded price on BSE in Rs at 02:45 pm | ||||
| M-cap - Market capitalisation lost in Rs crore | ||||
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%